Please note that this post contains affiliate links and any sales made through such links will reward MageeNews.com a small commission – at no extra cost to you.
I want to share an important update about Lilly’s efforts to address insulin affordability. In response to the crisis caused by COVID-19, Lilly is introducing the Lilly Insulin Value Program, allowing anyone with commercial insurance and those without insurance to fill their monthly prescription of Lilly insulin for $35. The program is effective today and covers most Lilly insulins. Details and more information can be found in the press release here: https://e.lilly/2wjEr7J.
Lilly has introduced several solutions in recent years to help meet the individual financial circumstances of people living with diabetes that are still in effect during the COVID-19 crisis, including:
The Lilly Diabetes Solution Center, through which representatives can direct people to the $35 savings card, as well as affordability options that may reduce their out-of-pocket costs further – such as free insulin for people with minimal income, or no income at all, that has been donated by Lilly to non-profit organizations.
Three non-branded versions of our insulin options with list prices 50 percent lower than the branded versions.
In January, the company announced plans to donate at least 200,000 KwikPens® to relief agencies over the next three years.
